CMPX
NASD Compass Therapeutics, Inc.$0.9296 ↓ -0.0079 (-0.84%) Trading Down from the previous close of $0.9375, $0.0604 below the day’s high of $0.9900
- YTD change
- -82.69%
- vs 20-day SMA
- -28.07%
- vs 200-day SMA
- -73.63%
Price ranges
Price & Performance
-4.26 (-81.97%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 86.5% away from all-time highs of $6.8800
- CMPX is down 83% since the beginning of the year
- CMPX is down 78% over the past 12 months
- CMPX is down 54% over the past 1 month
- 2% of all CMPX investors are betting against CMPX
CMPX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -78.1%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0204
- Last 5 days
- +8.51%
- vs 8-day SMA
- -4.08%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
